帕利哌酮缓释片治疗儿童期首发精神分裂症37例的疗效及安全性  

Efficacy and safety of paliperidone ER in the treatment of adolescent patients with first-episode schizophrenia

作　　者：孙凌[1] 周天红[1] 雷彤[1] 

机构地区：[1]天津市安定医院,天津300222

出　　处：《中国新药杂志》2011年第9期799-802,共4页Chinese Journal of New Drugs

摘　　要：目的:探讨帕利哌酮缓释片治疗儿童期首发精神分裂症患者临床疗效及安全性。方法:对37例儿童期首发精神分裂症患者应用帕利哌酮缓释片治疗,观察6个月。采用阳性与阴性症状量表(PANSS)、个人和社会功能量表(PSP)评定临床疗效,并通过治疗满意度调查问卷(MSQ)调查治疗满意度;采用副反应量表(TESS)评定不良反应,并进行实验室监测。结果:观察结束时总有效率为86.5%;PANSS总分、阳性症状分量表、一般精神病理分量表评分于治疗4 d起较治疗前有所下降(P<0.05),于治疗1周末、2周末、3月末、6月末,均较治疗前有显著下降(P<0.01);阴性症状分量表评分于治疗1周时有所下降(P<0.05),于治疗2周末、3月末、6月末,均较治疗前有显著下降(P<0.01)。不良反应轻微,多可自行缓解。社会功能明显改善,治疗满意度为81.1%。结论:帕利哌酮缓释片治疗儿童期首发精神分裂症患者起效快,疗效确切,不良反应轻微,安全性高,依从性好。Objective：To evaluate the efficacy and safety of paliperidone ER in the treatment of adolescent patients with first-episode schizophrenia.Methods：All patients（n=37） were treated with paliperidone ER for 6 months.The primary efficacy measure was response rate.Positive and Negative Syndrome Scale（PANSS）,Personal and Social Performance（PSP） and Medication Satisfaction Questionnaire（MSQ） were adopted as secondary efficacy measures.Treatment Emergent Symptom Scale（TESS） and laboratory examinations were adopted as safety measures.Results：The response rate was 86.5% at end point.Total PANSS score,positive scale and general psychopathology scale scores demonstrated a significant improvement after 4-day,1-week,2-week,3-month and 6-month treatment（P0.05）.Negative scale score was significantly reduced after 1-week,2-week,3-month and 6-month treatment（P0.05）.The adverse events were minimal and most of them were alleviated without any special intervention.Social functioning was also significantly improved.Medication satisfaction rate was 81.1%.Conclusion：Paliperidone ER is fast onset and effective in improving the symptoms of schizophrenia and social functioning.It has demonstrated a favorable safety with good compliance for adolescent patients.

关 键 词：帕利哌酮缓释片 精神分裂症 儿童 疗效 安全性 社会功能 

分 类 号：R971.41[医药卫生—药品]